Przejdź do zawartości
Merck

Przejdź do

K2144

Ko143 hydrate

≥98% (HPLC), powder, BCRP inhibitor

Synonim(y):

(3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-( 2-methylpropyl)-1,4-dioxopyrazino[1′,2′:1,6]pyrido[3,4- b]indole-3-propanoic acid 1,1-dimethylethyl ester hydrate, Ko-143 hydrate

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

Zmień widok
Gabaryty przesyłkiSKUDostępnośćCena netto
1 mg
Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
593,00 zł
5 mg
Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
2900,00 zł

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C26H35N3O5 · xH2O
Numer CAS:
Masa cząsteczkowa:
469.57 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:

593,00 zł


Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności

Zamów zamówienie zbiorcze
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc


Nazwa produktu

Ko143 hydrate, ≥98% (HPLC)

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: >10 mg/mL

originator

GlaxoSmithKline

storage temp.

room temp

SMILES string

O.COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O

InChI

1S/C26H35N3O5.H2O/c1-14(2)11-20-23-17(16-8-7-15(33-6)12-19(16)27-23)13-21-24(31)28-18(25(32)29(20)21)9-10-22(30)34-26(3,4)5;/h7-8,12,14,18,20-21,27H,9-11,13H2,1-6H3,(H,28,31);1H2/t18-,20-,21-;/m0./s1

InChI key

ZXXZDXPNJJZRDC-PSLBYKFTSA-N

Application

Ko143 hydrate has been used:
  • to determine the role of ATP-binding cassette sub-family G member 2 (ABCG2), human embryonic kidney (HEK)-C1 and HEK-ABCG2 in tumor microenvironment
  • to inhibit ABCG2 for sphere formation assay
  • in calcein-AM efflux inhibition to monitor multidrug resistance protein (MRP)-function in kidney
  • for cell viability assay

Biochem/physiol Actions

Ko143 has been used as a positive control inhibitor on functions of BCRP in MCF7 and BCRP over-expressing MCF7/MX100 cell lines using a BCRP prototypical substrate mitoxantrone.
Ko143 has been used as a positive control inhibitor on functions of BCRP in MCF7 and BCRP over-expressing MCF7/MX100 cell lines using a BCRP prototypical substrate mitoxantrone. The ABCG2 transporter breast cancer resistance protein (BCRP) plays an important role in disposition of many drugs and environmental toxins. Ko143 displays > 200-fold selectivity over P-gp and MRP-1 transporters. It increases intracellular drug accumulation and reverse BCRP-mediated multidrug resistance. It blocked topotecan and ABZSO transport in a concentration-dependent manner. Ko143 is reported to be a more specific inhibitor of BCRP than other known inhibitors of BCRP such as fumitremorgin C and GF120918.
Ko143 has been used as a positive control inhibitor on functions of breast cancer resistance protein (BCRP) using a BCRP prototypical substrate mitoxantrone.
Ko143 has been used as a positive control inhibitor on functions of breast cancer resistance protein (BCRP) using a BCRP prototypical substrate mitoxantrone. BCRP, an ABCG2 transporter, plays an important role in disposition of many drugs and environmental toxins. Ko143 displays > 200-fold selectivity over P-gp and MRP-1 transporters and thus is more specific than other known BCRP inhibitors such as fumitremorgin C and GF120918. It increases intracellular drug accumulation and reverses BCRP-mediated multidrug resistance. It blocks topotecan and ABZSO transport in a concentration-dependent manner.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

The stability of this product in solution has not been determined. According to various sources this product can be stored in solvent (DMSO) at -80°C for 6 months and -20°C for 1 month.
Ta strona może zawierać tekst przetłumaczony maszynowo.

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 1

Ta pozycja
SML0283A4111D6571
form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥95% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

room temp

storage temp.

room temp

storage temp.

2-8°C

storage temp.

room temp

solubility

DMSO: >10 mg/mL

solubility

DMSO: ≥5 mg/mL (warmed)

solubility

DMSO: 10 mg/mL, clear

solubility

DMSO: ≥20 mg/mL

color

white to off-white

color

white to beige

color

-

color

white to off-white


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Klasa składowania

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów


Produkty

Discover Bioactive Small Molecules for ADME/Tox

Protein-based drug transporters are expressed in Sf9 cells. Understanding the specific mechanisms of tumor cell transporters is an essential aspect of chemotherapeutic drug design.


Multi-drug resistance ABC transporter inhibition enhances murine ventral prostate stem/progenitor cell differentiation
Samant MD, et al.
Stem Cells and Development, 24(10), 1236-1251 (2015)
Jae Guen Song et al.
Cancer chemotherapy and pharmacology, 78(4), 735-744 (2016-08-16)
The present study aimed to discover a new potent BCRP inhibitor overcoming multidrug resistance. Effects of LW6 on the functional activity and gene expression of two major efflux transporters, BCRP and P-gp, were evaluated by using MDCKII cells overexpressing each
Overcoming resistance to the THZ series of covalent transcriptional CDK inhibitors
Gao Y, et al.
Cell Chemical Biology, 25(2), 135-142 (2018)



Numer pozycji handlu globalnego

SKUNUMER GTIN
K2144-1MG04061833868287
K2144-5MG04061833868294

Questions

  1. Dear all, once I dissolved  the compound in DMSO I should store it in the fridge or at lower temperatures? 

    1 answer
    1. The stability of this product in solution has not been determined. According to various sources this product can be stored in solvent (DMSO) at -80°C for 6 months and -20°C for 1 month. This information has not been validated.

      Helpful?

Reviews

No rating value

Active Filters